Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression

CompletedOBSERVATIONAL
Enrollment

76

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

December 5, 2019

Conditions
Bipolar Disorder
Interventions
DIAGNOSTIC_TEST

Pharmacogenomic-testing with NEUROPHARMAGEN

"This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information."

Trial Locations (1)

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors
collaborator

Hospital Clinic of Barcelona

OTHER

lead

AB Biotics, SA

INDUSTRY

NCT04923204 - Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression | Biotech Hunter | Biotech Hunter